GlassScriptPhysician profile
Amy Kien Tra
NPI 1043875370
$15,634.66
in general payments reported to CMS, 2019-2025
40 companies · $4,804 in 2025
The $4,804 reported for 2025 was more than what 98% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,976 · 2022: $3,061 · 2023: $2,650 · 2024: $3,143 · 2025: $4,804.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,365.40 |
| Education | $232.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,865.51 | 2021-2025 | |
| Janssen Biotech, INC. | $1,357.12 | 2021-2025 | Stelara, Tremfya, Simponi Aria |
| Qol Medical, LLC | $1,228.17 | 2021-2025 | Sucraid, Sucraid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,219.57 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $1,196.86 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Pfizer INC. | $940.31 | 2021-2025 | |
| Genzyme Corporation | $788.04 | 2022-2025 | |
| Madrigal Pharmaceuticals | $474.84 | 2024-2025 | Rezdiffra, Resmetirom |
| Celgene Corporation | $474.11 | 2021-2024 | Zeposia |
| Lilly USA, LLC | $400.93 | 2024-2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $398.88 | 2022-2025 | Dupixent |
| Ardelyx, INC. | $311.41 | 2023-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $273.33 | 2021-2025 | Linzess |
| Redhill Biopharma INC. | $264.88 | 2021-2023 | Talicia, Aemcolo, Movantik |
| Celltrion USA INC. | $246.29 | 2024-2025 | Vegzelma, Zymfentra |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Tra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.